Postchemotherapy Immunization Practices for Non-HSCT Pediatric Oncology Patients

Area of Science:

• Pediatric Oncology
• Immunology
• Infectious Disease Prevention

Background:

• Antineoplastic therapy in pediatric oncology patients compromises immune systems, leading to loss of protective antibodies.
• Reimmunization is crucial for protecting these vulnerable patients against vaccine-preventable diseases.
• Existing recommendations for reimmunization are heterogeneous, with limited data on current clinical practices.

Purpose of the Study:

• To describe the current reimmunization practices among pediatric oncologists for patients undergoing non-hematopoietic stem cell transplantation.
• To identify variations in clinical practice and the availability of standardized guidelines.

Main Methods:

• A survey was distributed to Children's Oncology Group (COG)-identified principal investigators.
• The survey captured institutional practices regarding the reimmunization of pediatric oncology patients.
• Data included methods of immune status assessment and availability of institutional guidelines.

Main Results:

• The majority of pediatric oncologists surveyed do not routinely assess vaccine-related immune status.
• When assessed, immune status was most commonly checked 6 months post-therapy cessation, using methods like vaccine titers or absolute lymphocyte counts.
• Over half of the surveyed institutions lacked standardized reimmunization guidelines, with smaller institutions more likely to check vaccine titers.

Conclusions:

• Significant variations exist in pediatric oncologists' reimmunization practices, even with available recommended schedules.
• The lack of standardized guidelines and consistent immune status assessment highlights a need for further research.
• Identifying optimal, cost-effective strategies for ensuring infectious disease immunity post-cancer treatment is essential.